EQS-News: Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm

Berlin, 24 April 2025. Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials.

Y90-PentixaTher is a radiolabeled peptide therapeutic designed to deliver targeted radiation to cancer cells that overexpress the CXCR4 receptor - commonly found in malignancies such as acute myeloid leukemia, lymphoma, myeloma and various solid tumors. Used alongside the radiodiagnostic Ga68-PentixaFor, it supports a theranostic approach that allows physicians to visualize the disease before and after treatment.

As part of the newly signed agreement, EZR will manufacture Y90-PentixaTher under GMP conditions and manage the direct shipment of individual patient doses to trial sites. The agreement is limited to the clinical development phase and does not extend to commercial-scale manufacturing. Pentixapharm retains full strategic flexibility under this agreement to determine its future development and commercial supply.

“With this agreement, we are proud to support the advancement of Pentixapharm’s clinical oncology program,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE (EZAG). “Reliable access to high-quality radioisotopes is critical for the development of next-generation radiopharmaceuticals, and we are pleased to contribute our manufacturing excellence to accelerate the delivery of innovative cancer therapies.”

“Securing a reliable Y90-PentixaTher GMP production is a significant milestone for Pentixapharm,” said Dr. Dirk Pleimes, CEO of Pentixapharm AG. “This agreement marks a critical step in securing reliable clinical supply as we advance our targeted radiopharmaceutical therapies toward late-stage development.”

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDax index of Deutsche Börse.
Contributing to saving lives

About Pentixapharm
Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based, first-in-class radiopharmaceuticals with strong differentiation and commercialization potential across high-need diagnostic and therapeutic areas. Its pipeline comprises CXCR4-targeted compounds in clinical development and a portfolio of early-stage radionuclide-antibody conjugates, aimed at treating hematologic malignancies, solid tumors, and diseases of the cardiovascular, endocrine, and immune systems.

Contact:
Eckert & Ziegler SE 
Robert-Rössle-Str. 10, 13125 Berlin, Germany 
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations 
jan.schoepflin@ezag.com / karolin.riehle@ezag.com 
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com 

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
ir@pentixapharm.com
Tel. +49 30 94893232
www.pentixapharm.com